Benzinga | Jul 23, 2020 02:32PM EDT

Protalix reports Non-Binding Term Sheet With SarcoMed To Develop Alidornase Alfa For Treatment Of Pulmonary Sarcoidosis, Related Diseases

Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx(r) plant cell-based protein expression system, today announced that it has entered into a non-binding term sheet with SarcoMed USA Inc. The arrangement, if consummated, would relate to the development and commercialization of PRX--110, or alidornase alfa, for the treatment of Pulmonary Sarcoidosis and related diseases. SarcoMed USA was formed in 2017 to investigate if a novel DNase 1 compound could influence the chronic pulmonary inflammation seen in Pulmonary Sarcoidosis patients.





On July 21, 2020, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for alidornase alfa for the treatment of Sarcoidosis. The FDA grants Orphan Drug Designation to drugs or biologics intended to treat or prevent rare diseases or conditions that affect fewer than 200,000 individuals in the United States.

About Protalix BioTherapeutics, Inc.